Apolipoprotein E in Asthmatic Inflammatory Response: Friend or Foe?

Qin, Shugang; Pu, Qinqin; Wang, Zhihan; Wu, Min

doi:10.1165/rcmb.2020-0106ed

“…Additionally, apolipoprotein E (APOE) was also reported to be downregulated in progressive as well as stable vitiligo patients compared to healthy controls, with the protein being more downregulated in stable vitiligo than the progressive form. Different sources imply that this protein has anti-inflammatory as well as pro-inflammatory properties ( 23 – 25 ). Finally, mannose-binding protein C (MBL2) was downregulated in progressive vitiligo compared to healthy controls, while it was upregulated in stable vitiligo patients compared to controls.…”

Section: Resultsmentioning

confidence: 99%

“…Different sources imply that this protein has anti-inflammatory as well as pro-inflammatory properties (23)(24)(25). Finally, mannosebinding protein C (MBL2) was downregulated in progressive vitiligo compared to healthy controls, while it was upregulated in stable vitiligo patients compared to controls.…”

Section: Protein Identification Of the Study Ratiomentioning

confidence: 99%

Proteomics data in vitiligo: a scoping review

Berrevoet,

Van Nieuwerburgh,

Deforce

et al. 2024

Front. Immunol.

0

View full text Add to dashboard Cite

An unbiased screening of which proteins are deregulated in vitiligo using proteomics can offer an enormous value. It could not only reveal robust biomarkers for detecting disease activity but can also identify which patients are most likely to respond to treatments. We performed a scoping review searching for all articles using proteomics in vitiligo. Eight manuscripts could be identified. Unfortunately, very limited overlap was found in the differentially expressed proteins between studies (15 out of 272; 5,51%) with variable degrees of the type of proteins and a substantial variety in the prevalence of acute phase proteins (range: 6-65%). Proteomics research has therefore brought little corroborating evidence on which proteins are differentially regulated between vitiligo patients and healthy controls or between active and stable vitiligo patients. While a limited patient size is an obvious weakness for several studies, an incomplete description of patient characteristics is an unfortunate and avoidable shortcoming. Additionally, the variations in the used methodology and analyses may further contribute to the overall observed variability. Nonetheless, more recent studies investigating the response to treatment seem to be more robust, as more differentially expressed proteins that have previously been confirmed to be involved in vitiligo were found. The further inclusion of proteomics analyses in clinical trials is recommended to increase insights into the pathogenic mechanisms in vitiligo and identify reliable biomarkers or promising drug targets. A harmonization in the study design, reporting and proteomics methodology could vastly improve the value of vitiligo proteomics research.

show abstract

“…We compared post-treatment asthmatic patients with healthy subjects, and found that the expression of apolipoprotein was higher after treatment with ICS/LABA. Apolipoprotein plays a major role in lipid metabolism and exerts both pro-and anti-inflammatory effects [20]. Apolipoprotein regulates inflammation, which may be dependent on cell types and disease models [20].…”

Section: Discussionmentioning

confidence: 99%

“…Apolipoprotein plays a major role in lipid metabolism and exerts both pro-and anti-inflammatory effects [20]. Apolipoprotein regulates inflammation, which may be dependent on cell types and disease models [20]. Gordon et al suggested apolipoprotein functions as an endogenous danger signal that activates the inflammasome of macrophages to secrete IL-1β and induces airway inflammation in asthmatic subjects [21].…”

Section: Discussionmentioning

confidence: 99%

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids

Liang¹,

Tzeng²,

Hsieh³

et al. 2022

View full text Add to dashboard Cite

Introduction: Asthma is one of the major public health problems that imposes a great burden on societal, financial, and healthcare around the world. Asthma poorly affects the health-related quality of life and daily activities of patients. Treatment of asthma, including inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), mainly aims to improve the lung function and reduce symptoms and exacerbations. Current treatment regimens are symptom-based strategies, and the status of airway inflammation after treatment is yet unknown. We conducted this study to understand the comprehensive inflammation or airway remodeling status of patients after ICS-LABA treatment through RNA transcriptome analysis. Materials and methods: Eight newly diagnosed asthmatic patients and two healthy subjects were recruited in this study. Asthmatic patients underwent blood tests, lung function test, and RNA transcriptome analysis before and after ICS-LABA treatment. Results: In comparison with healthy subjects, pretreatment asthmatic patients had higher expression of protein tyrosine kinase and related signaling pathways. After ICS-LABA treatment, the expression of nuclear receptor transcription coactivator, N-acetyltransferase, protein tyrosine kinase, nuclear receptor, and RNA polymerase II-activating transcription factor were downregulated. However, the post-treatment asthmatic patients still had higher expression of cysteine-type endopeptidase, endodeoxyribonuclease, apolipoprotein, and unfolded protein was still upregulated than healthy subjects. Conclusions: The combination of ICS/LABAs decreased airway inflammatory and remodeling pathways. However, allergen stimulation-related pathways were still upregulated in patients after ICS/LABA treatment. The combination of medication and allergen removal is a complete strategy for asthma.

show abstract

“…Different sources imply that this protein has anti-inflammatory as well as pro-inflammatory properties. (21)(22)(23) Finally, mannosebinding protein C (MBL2) was downregulated in progressive vitiligo compared to healthy controls, while it was upregulated in stable vitiligo patients compared to controls. This protein has been reported as an acute phase protein in response to inflammation.…”

Section: Studies Investigating Vitiligo Patients Versus Healthy Contr...mentioning

confidence: 99%

Proteomics data in vitiligo: a scoping review

Berrevoet,

Van Nieuwerburgh,

Deforce

et al. 2024

Preprint

0

View full text Add to dashboard Cite

An unbiased screening of which proteins are deregulated in vitiligo using proteomics can offer an enormous value. It could not only reveal robust biomarkers for detecting disease activity but can also identify which patients are most likely to respond to treatments. We performed a scoping review searching for all articles using proteomics in vitiligo. Eight manuscripts could be identified. Unfortunately, very limited overlap was found in the differentially expressed proteins between studies (15 out of 272; 5,51%) with variable degrees of the type of proteins and a substantial variety in the prevalence of acute phase proteins (range: 6-65%). Proteomics research has therefore brought little corroborating evidence on which proteins are differentially regulated between vitiligo patients and healthy controls or between active and stable vitiligo patients. While a limited patient size is an obvious weakness for several studies, an incomplete description of patient characteristics is an unfortunate and avoidable shortcoming. Additionally, the variations in the used methodology and analyses may further contribute to the overall observed variability. Nonetheless, more recent studies investigating the response to treatment seem to be more robust, as more differentially expressed proteins that have previously been confirmed to be involved in vitiligo were found. The further inclusion of proteomics analyses in clinical trials is recommended to increase insights into the pathogenic mechanisms in vitiligo and identify reliable biomarkers or promising drug targets. A harmonization in the study design, reporting and proteomics methodology could vastly improve the value of vitiligo proteomics research.

show abstract

Apolipoprotein E in Asthmatic Inflammatory Response: Friend or Foe?

Cited by 4 publications

References 13 publications

Proteomics data in vitiligo: a scoping review

Proteomics data in vitiligo: a scoping review

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids

Proteomics data in vitiligo: a scoping review

Contact Info

Product

Resources

About